M. Eefting

发表

Donor T-cell responses and disease progression patterns of multiple myeloma

H. Putter, H. Veelken, J. Schetelig, 2017, Bone Marrow Transplantation.

Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion

H. Putter, H. Veelken, P. A. von dem Borne, 2016, Haematologica.

Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation

H. Veelken, P. A. von dem Borne, S. Kersting, 2014, Haematologica.

Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program

E. Vellenga, B. Biemond, G. Huls, 2011 .

Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL

R. Willemze, H. Veelken, S. Kersting, 2014, Bone Marrow Transplantation.

Integrated Whole Genome and Transcriptome Analysis Identified a Therapeutic Minor Histocompatibility Antigen in a Splice Variant of ITGB2

M. Vermaat, P. Hoen, M. Kester, 2016, Clinical Cancer Research.

Predictors of short-term and long-term mortality in critically ill patients admitted to the intensive care unit following allogeneic stem cell transplantation

S. le Cessie, P. Tuinman, M. Arbous, 2018, Bone Marrow Transplantation.

Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL

R. Willemze, H. Veelken, S. Kersting, 2014, Bone Marrow Transplantation.

CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity.

W. Marijt, L. D. de Wreede, I. Jedema, 2018, Transplant immunology.

Erratum to: Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib

I. Touw, P. Valk, K. Lom, 2015, Annals of Hematology.

Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib

I. Touw, P. Valk, K. Lom, 2014, Annals of Hematology.